Company news
Sutro Biopharma, Inc. (NASDAQ:STRO) news
Sutro Biopharma, Inc. news releases on 6ix. Latest, Apr 27, 2020: Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation…
Press releases — page 3
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
April 26, 2020
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
April 19, 2020
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
March 15, 2020
Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
March 11, 2020
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
February 4, 2020
Sutro Biopharma Appoints James Panek to Board of Directors
January 7, 2020
Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments
November 7, 2019
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 15, 2019
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
October 7, 2019
Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments
August 13, 2019
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
March 31, 2019